logo
Sign in

TriSalus Life Sciences, Inc.

WESTMINSTER, CO · Founded 2020 · Biotech · Public

Drug delivery technology platform integrated with immunotherapy for solid tumors

Claim this profile

Follows are private to you and power your alerts

Updated · trisaluslifesci.com

Sector
Biotech
Headquarters
WESTMINSTER, CO
Founded
2020
Latest Form D
$22M, May 2025
Total capital
$40.9M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$40.9M
3 Form D · last May 2025
18 months since last filing
Federal contracts
$22K
2 awards · Veterans Affairs
Rank in Biotech#371 of 4373
Granted patents
18
22 pending · first 2022
Rank in peer group#1 of 28

Capital timeline

20112013201520172019202120232025FEDERAL ↑EQUITY ↓Cumulative $40.9M$17K$6K1st Form D$17.9M
2011201520192023FEDERAL ↑EQUITY ↓Cumulative $40.9M$17K$6K1st Form D$17.9M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$22M
  • Private capital raisedForm D · SEC · 2nd filing$1.0M
  • Private capital raisedForm D · SEC · 1st filing$17.9M
  • Federal contractVeterans Affairs · Catheter$6K
  • Federal contractVeterans Affairs · Infusion System Microcatheter Guide Sheath&rotating Hemostatic Valve$17K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

138months

from TriSalus Life Sciences, Inc.’s first federal award to its first private round.

First federal award · Dec 2011
Veterans Affairs · $17K
First Form D · Jun 2023
$17.9M · 1st Form D
Awards before first raise
2 awards

An association in public records, not a cause or a prediction.

Standing among 28 peers

Line = median

Biotech · System

  • Granted patents#1 · top 4%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Andrew B. von EschenbachDirectorNamed in SEC Form D filings
  • Anil SinghalDirectorNamed in SEC Form D filings
  • Arjun F. DesaiDirectorNamed in SEC Form D filings
  • Brian F. CoxExecutive OfficerNamed in SEC Form D filings
  • Bryan F. CoxExecutive OfficerNamed in SEC Form D filings
  • David Kelly MatlinDirectorNamed in SEC Form D filings
Show all 23 people
  • Diane ParksDirectorNamed in SEC Form D filings
  • Gary F. GordonDirectorNamed in SEC Form D filings
  • Gene McGrevinDirectorNamed in SEC Form D filings
  • George Kelly MartinDirectorNamed in SEC Form D filings
  • James YoungExecutive OfficerNamed in SEC Form D filings
  • Jennifer E. StevensExecutive OfficerNamed in SEC Form D filings
  • Jodi Kelly DevlinExecutive OfficerNamed in SEC Form D filings
  • John L. TullisDirectorNamed in SEC Form D filings
  • Kerry HicksDirectorNamed in SEC Form D filings
  • Liselotte B. HyveledDirectorNamed in SEC Form D filings
  • Mary SzelaExecutive Officer, DirectorNamed in SEC Form D filings
  • Mats L. WahlstromDirectorNamed in SEC Form D filings
  • Raj L. MistryExecutive OfficerNamed in SEC Form D filings
  • Richard J. MarshakExecutive OfficerNamed in SEC Form D filings
  • Sean MurphyDirectorNamed in SEC Form D filings
  • Simone SongDirectorNamed in SEC Form D filings
  • William F. ValleDirectorNamed in SEC Form D filings

What it has protected

USPTO · 18 granted of 40
Show all 40 patent records

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .